# Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

> **NCT01243125** · PHASE2 · COMPLETED · sponsor: **NovaBay Pharmaceuticals, Inc.** · enrollment: 67 (actual)

## Conditions studied

- Urinary Catheter Blockage and Encrustation

## Interventions

- **DRUG:** NVC-422, 0.2%
- **DRUG:** Sterile normal saline, 0.9%

## Key facts

- **NCT ID:** NCT01243125
- **Lead sponsor:** NovaBay Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243125, "Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01243125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*